copper sulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4282	7758-99-8

Description:

Molecule	Description
Synonyms: cupric sulfate copper sulfate copper sulfate pentahydrate cupric sulfate pentahydrate cupric sulfate anhydrous	A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae. Molecular weight: 159.60 Formula: CuO4S CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

cupric sulfate
copper sulfate
copper sulfate pentahydrate
cupric sulfate pentahydrate
cupric sulfate anhydrous

A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.

Molecular weight: 159.60
Formula: CuO4S
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 5, 1987	FDA	ABRAXIS PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contraindicated product administered	120.13	11.13	4	40273	217644	63231101
Treatment failure	91.08	11.13	10	40267	199033	63249712
Product dose omission issue	87.11	11.13	336	39941	233977	63214768
Systemic lupus erythematosus	85.03	11.13	15	40262	208903	63239842
Maternal exposure during pregnancy	84.92	11.13	18	40259	220044	63228701
Drug intolerance	83.46	11.13	46	40231	308615	63140130
Product use issue	83.15	11.13	19	40258	220501	63228244
Product use in unapproved indication	81.92	11.13	9	40268	179071	63269674
Diarrhoea	81.19	11.13	749	39528	714617	62734128
Glossodynia	76.94	11.13	11	40266	178865	63269880
Muscle spasms	74.37	11.13	243	40034	155907	63292838
Infusion related reaction	68.69	11.13	35	40242	245486	63203259
Pericarditis	67.40	11.13	4	40273	131575	63317170
Toxicity to various agents	66.59	11.13	37	40240	247213	63201532
Off label use	66.18	11.13	214	40063	674248	62774497
Drug ineffective	64.78	11.13	394	39883	1044371	62404374
Device expulsion	61.20	11.13	92	40185	34830	63413915
Wound	59.69	11.13	15	40262	163248	63285497
Unevaluable event	56.46	11.13	110	40167	51276	63397469
Fall	54.96	11.13	431	39846	391903	63056842
Psoriasis	52.35	11.13	147	40130	86810	63361935
Therapeutic product effect decreased	51.87	11.13	29	40248	193158	63255587
Arthropathy	50.22	11.13	45	40232	234747	63213998
Full blood count decreased	49.12	11.13	71	40206	25953	63422792
Fatigue	47.88	11.13	809	39468	887219	62561526
Device dislocation	46.88	11.13	69	40208	25636	63423109
Intentional product use issue	44.39	11.13	13	40264	127879	63320866
Helicobacter infection	44.14	11.13	4	40273	92781	63355964
Therapy cessation	43.39	11.13	73	40204	30384	63418361
Dizziness	42.09	11.13	437	39840	429488	63019257
Drug hypersensitivity	41.62	11.13	84	40193	310603	63138142
Neuropathy peripheral	41.33	11.13	162	40115	113505	63335240
Lower respiratory tract infection	39.84	11.13	17	40260	132290	63316455
Therapeutic product effect incomplete	39.40	11.13	15	40262	125041	63323704
Hepatic enzyme increased	37.34	11.13	44	40233	202284	63246461
Deep vein thrombosis	36.83	11.13	127	40150	83673	63365072
Asthenia	36.61	11.13	388	39889	383216	63065529
Intentional overdose	35.81	11.13	3	40274	74149	63374596
Nausea	33.21	11.13	741	39536	853730	62595015
Pneumonia	32.17	11.13	436	39841	456331	62992414
Feeling abnormal	31.56	11.13	181	40096	148211	63300534
Folliculitis	30.98	11.13	4	40273	70313	63378432
C-reactive protein increased	30.44	11.13	11	40266	94696	63354049
Plasma cell myeloma	30.28	11.13	69	40208	35836	63412909
Flatulence	29.61	11.13	67	40210	34635	63414110
General physical health deterioration	28.20	11.13	53	40224	201349	63247396
Constipation	28.12	11.13	241	40036	224702	63224043
Laboratory test abnormal	27.61	11.13	56	40221	26856	63421889
Headache	26.73	11.13	556	39721	632685	62816060
Joint swelling	26.72	11.13	112	40165	327554	63121191
Discomfort	26.22	11.13	41	40236	167333	63281412
Haemoglobin decreased	25.60	11.13	169	40108	145316	63303429
Drug interaction	24.28	11.13	70	40207	229061	63219684
Injection site pain	24.19	11.13	153	40124	129647	63319098
Rheumatoid arthritis	23.76	11.13	82	40195	253737	63195008
Liver injury	23.22	11.13	5	40272	60515	63388230
Hypoaesthesia	22.95	11.13	184	40093	168209	63280536
Exposure during pregnancy	22.60	11.13	40	40237	155507	63293238
Back pain	21.89	11.13	260	40017	263885	63184860
Suicide attempt	21.48	11.13	6	40271	60912	63387833
Pelvic pain	21.41	11.13	34	40243	13485	63435260
Memory impairment	21.39	11.13	126	40151	104132	63344613
Hot flush	21.15	11.13	76	40201	51083	63397662
Fluid retention	20.82	11.13	84	40193	59602	63389143
Injection site haemorrhage	20.80	11.13	47	40230	24267	63424478
COVID-19	20.42	11.13	25	40252	113078	63335667
Dehydration	20.23	11.13	183	40094	173171	63275574
Overdose	20.19	11.13	26	40251	115052	63333693
Irritable bowel syndrome	19.85	11.13	14	40263	82398	63366347
Alopecia	19.85	11.13	129	40148	337407	63111338
Dry skin	19.80	11.13	80	40197	56807	63391938
Depression	19.28	11.13	200	40077	196292	63252453
Blister	19.21	11.13	33	40244	129781	63318964
Injection site erythema	18.69	11.13	103	40174	83071	63365674
Pulmonary embolism	18.42	11.13	132	40145	116552	63332193
Eye swelling	18.03	11.13	44	40233	23874	63424871
Nasal congestion	18.02	11.13	86	40191	65574	63383171
Influenza like illness	17.97	11.13	87	40190	66737	63382008
Urinary tract infection	17.90	11.13	251	40026	264433	63184312
Hip fracture	16.92	11.13	49	40228	29425	63419320
Dyspnoea	16.80	11.13	543	39734	660770	62787975
Type 2 diabetes mellitus	16.54	11.13	10	40267	63858	63384887
Blood potassium decreased	16.16	11.13	61	40216	41965	63406780
Hypersensitivity	16.13	11.13	114	40163	292571	63156174
Hypervolaemia	16.08	11.13	47	40230	28366	63420379
Ill-defined disorder	15.92	11.13	17	40260	81738	63367007
Injection site reaction	15.59	11.13	76	40201	58448	63390297
Skin discolouration	15.46	11.13	56	40221	37772	63410973
Pulmonary arterial hypertension	15.41	11.13	40	40237	22537	63426208
Vaginal haemorrhage	15.11	11.13	45	40232	27442	63421303
Condition aggravated	15.02	11.13	173	40104	402044	63046701
Tremor	14.12	11.13	137	40140	132102	63316643
White blood cell count decreased	13.83	11.13	142	40135	138962	63309783
Product complaint	13.55	11.13	27	40250	12782	63435963
Asthma	13.48	11.13	39	40238	127522	63321223
Hypoxia	13.40	11.13	74	40203	59718	63389027
Administration site swelling	13.29	11.13	9	40268	1298	63447447
Intestinal dilatation	13.24	11.13	10	40267	1712	63447033
Paraesthesia	13.20	11.13	155	40122	156811	63291934
Plasma cell myeloma recurrent	13.13	11.13	13	40264	3200	63445545
Atrial fibrillation	13.03	11.13	122	40155	116514	63332231
Body height decreased	12.84	11.13	23	40254	10055	63438690
Abdominal discomfort	12.77	11.13	136	40141	320749	63127996
Pulmonary hypertension	12.75	11.13	52	40225	37071	63411674
Impaired healing	12.64	11.13	29	40248	102513	63346232
Hospice care	12.63	11.13	20	40257	7912	63440833
Balance disorder	12.46	11.13	94	40183	84328	63364417
Chest pain	12.34	11.13	199	40078	215760	63232985
Oedema peripheral	12.12	11.13	178	40099	189333	63259412
Swelling	12.08	11.13	114	40163	275264	63173481
Depressed level of consciousness	11.98	11.13	13	40264	62065	63386680
Coma	11.86	11.13	14	40263	64350	63384395
Thrombosis	11.85	11.13	76	40201	64679	63384066
Dyspnoea exertional	11.80	11.13	72	40205	60230	63388515
Injection site mass	11.67	11.13	32	40245	18624	63430121
Injection site bruising	11.58	11.13	55	40222	41855	63406890
Foetal exposure during pregnancy	11.55	11.13	3	40274	31959	63416786
Intentional product misuse	11.49	11.13	13	40264	60904	63387841
Insomnia	11.43	11.13	196	40081	215056	63233689
Chills	11.39	11.13	116	40161	113262	63335483
Fibromyalgia	11.39	11.13	21	40256	80399	63368346
Infection	11.32	11.13	92	40185	229081	63219664
Gait disturbance	11.30	11.13	171	40106	183007	63265738
Dysgeusia	11.27	11.13	59	40218	46651	63402094
Red blood cell sedimentation rate increased	11.23	11.13	7	40270	43975	63404770

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	81.10	12.18	98	23394	419426	34514013
Product use in unapproved indication	63.15	12.18	4	23488	117495	34815944
Fatigue	59.64	12.18	439	23053	370214	34563225
Plasma cell myeloma	51.01	12.18	97	23395	41940	34891499
Product dose omission issue	50.58	12.18	186	23306	119525	34813914
Completed suicide	48.15	12.18	5	23487	98163	34835276
Respiratory tract infection bacterial	43.24	12.18	22	23470	1760	34931679
Diarrhoea	40.24	12.18	419	23073	389493	34543946
Respiratory tract infection viral	38.73	12.18	23	23469	2494	34930945
Full blood count decreased	38.72	12.18	54	23438	18034	34915405
Drug interaction	37.25	12.18	59	23433	225887	34707552
Laboratory test abnormal	36.57	12.18	56	23436	20335	34913104
Asthenia	34.03	12.18	281	23211	244970	34688469
Fall	33.43	12.18	242	23250	202643	34730796
Toxicity to various agents	32.38	12.18	53	23439	200309	34733130
White blood cell count decreased	31.99	12.18	138	23354	95307	34838132
Adverse drug reaction	31.11	12.18	64	23428	29278	34904161
Viral infection	25.61	12.18	44	23448	17579	34915860
General physical health deterioration	23.56	12.18	31	23461	128238	34805201
Psoriasis	23.28	12.18	68	23424	38744	34894695
Pneumonia	21.76	12.18	353	23139	362274	34571165
Influenza	20.79	12.18	77	23415	49589	34883850
Rash	20.38	12.18	234	23258	222518	34710921
Neuropathy peripheral	20.37	12.18	110	23382	83153	34850286
Platelet count decreased	19.79	12.18	143	23349	119574	34813865
Dizziness	19.74	12.18	229	23263	218292	34715147
Intentional product misuse	18.52	12.18	4	23488	45607	34887832
Interstitial lung disease	17.68	12.18	11	23481	65271	34868168
Muscle spasms	17.61	12.18	98	23394	74903	34858536
Sinusitis	17.16	12.18	64	23428	41338	34892101
Thrombosis	16.16	12.18	72	23420	50386	34883053
Hepatic function abnormal	15.90	12.18	5	23487	44358	34889081
Overdose	15.72	12.18	23	23469	91036	34842403
Multiple organ dysfunction syndrome	15.65	12.18	17	23475	76549	34856890
Treatment failure	15.47	12.18	6	23486	46691	34886748
Peripheral swelling	15.38	12.18	96	23396	76445	34856994
Constipation	15.36	12.18	150	23342	136832	34796607
Regurgitation	15.06	12.18	11	23481	1688	34931751
Drug ineffective	14.87	12.18	217	23275	456534	34476905
Eructation	14.68	12.18	17	23475	4714	34928725
Foetal exposure during pregnancy	14.19	12.18	4	23488	38097	34895342
Cardiac disorder	14.15	12.18	62	23430	43064	34890375
Flatulence	13.54	12.18	38	23454	21160	34912279
Influenza like illness	13.41	12.18	45	23447	27589	34905850
Coma	13.36	12.18	7	23485	45671	34887768
Small intestinal obstruction	12.99	12.18	30	23462	14836	34918603
Mental status changes	12.69	12.18	55	23437	38028	34895411
Memory impairment	12.53	12.18	60	23432	43258	34890181
Therapy cessation	12.43	12.18	32	23460	16941	34916498

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	130.48	10.95	6	50546	245761	79448075
Product use in unapproved indication	121.28	10.95	10	50542	250349	79443487
Off label use	120.43	10.95	247	50305	906968	78786868
Product dose omission issue	99.62	10.95	364	50188	247173	79446663
Toxicity to various agents	97.30	10.95	75	50477	421465	79272371
Contraindicated product administered	83.09	10.95	4	50548	157534	79536302
Treatment failure	79.35	10.95	8	50544	170478	79523358
Device expulsion	72.98	10.95	86	50466	25775	79668061
Fall	68.10	10.95	535	50017	487094	79206742
Drug intolerance	67.51	10.95	42	50510	264077	79429759
Product use issue	64.68	10.95	26	50526	209796	79484040
Drug ineffective	63.86	10.95	413	50139	1080500	78613336
Drug interaction	63.82	10.95	103	50449	415080	79278756
Diarrhoea	62.72	10.95	841	49711	879648	78814188
Fatigue	59.36	10.95	871	49681	928856	78764980
Dizziness	58.97	10.95	550	50002	525891	79167945
Plasma cell myeloma	58.55	10.95	114	50438	53145	79640691
Asthenia	58.53	10.95	537	50015	511152	79182684
Muscle spasms	54.96	10.95	238	50314	174492	79519344
Infusion related reaction	49.30	10.95	44	50508	230193	79463643
Intentional overdose	49.22	10.95	5	50547	105955	79587881
Therapy cessation	48.29	10.95	86	50466	37476	79656360
Systemic lupus erythematosus	46.46	10.95	10	50542	121139	79572697
Deep vein thrombosis	43.75	10.95	172	50380	120747	79573089
Full blood count decreased	41.91	10.95	67	50485	26752	79667084
Respiratory tract infection bacterial	41.27	10.95	22	50530	2055	79691781
Device dislocation	40.75	10.95	65	50487	25905	79667931
General physical health deterioration	40.66	10.95	70	50482	275168	79418668
Maternal exposure during pregnancy	38.79	10.95	19	50533	136519	79557317
Therapeutic product effect incomplete	38.33	10.95	21	50531	141624	79552212
Intentional product misuse	38.28	10.95	7	50545	95158	79598678
Drug hypersensitivity	36.46	10.95	85	50467	298831	79395005
Pneumonia	35.33	10.95	601	49951	659645	79034191
Lower respiratory tract infection	33.76	10.95	20	50532	129200	79564636
Glossodynia	33.17	10.95	12	50540	103325	79590511
Dehydration	32.74	10.95	269	50283	247918	79445918
Intentional product use issue	32.63	10.95	29	50523	152083	79541753
Overdose	31.88	10.95	42	50510	184164	79509672
Fluid retention	31.76	10.95	107	50445	69702	79624134
Respiratory tract infection viral	31.14	10.95	24	50528	4235	79689601
Haemoglobin decreased	31.06	10.95	244	50308	221875	79471961
Unevaluable event	30.61	10.95	91	50461	55494	79638342
Pericarditis	30.38	10.95	14	50538	104222	79589614
C-reactive protein increased	29.65	10.95	23	50529	129004	79564832
Duodenal ulcer perforation	28.58	10.95	4	50548	66207	79627629
Helicobacter infection	28.31	10.95	5	50547	69699	79624137
Nausea	27.75	10.95	798	49754	956398	78737438
Pulmonary embolism	27.06	10.95	194	50358	171460	79522376
Hypervolaemia	26.52	10.95	73	50479	42617	79651219
Arthropathy	26.18	10.95	45	50507	177066	79516770
Joint swelling	25.78	10.95	95	50457	288551	79405285
Feeling abnormal	25.72	10.95	181	50371	159018	79534818
Coma	25.70	10.95	16	50536	100633	79593203
Hospice care	25.34	10.95	32	50520	10292	79683544
Dyspnoea	24.95	10.95	715	49837	856310	78837526
Therapeutic product effect decreased	24.80	10.95	41	50511	163822	79530014
Hepatic enzyme increased	24.68	10.95	49	50503	182561	79511275
Injection site pain	24.21	10.95	153	50399	129685	79564151
Headache	23.83	10.95	562	49990	653210	79040626
Flatulence	23.57	10.95	70	50482	42654	79651182
Suicide attempt	22.86	10.95	12	50540	82920	79610916
Depressed level of consciousness	22.49	10.95	17	50535	96635	79597201
Mental status changes	22.42	10.95	93	50459	66866	79626970
Influenza like illness	22.00	10.95	97	50455	71610	79622226
Pelvic pain	21.69	10.95	34	50518	13347	79680489
Hip fracture	21.54	10.95	55	50497	30706	79663130
Hepatic function abnormal	21.02	10.95	10	50542	73097	79620739
Viral infection	20.51	10.95	67	50485	42949	79650887
Depression	20.08	10.95	218	50334	216572	79477264
Rheumatoid arthritis	19.69	10.95	67	50485	208403	79485433
Psoriasis	19.54	10.95	110	50442	89477	79604359
Therapeutic response decreased	19.45	10.95	9	50543	66844	79626992
Dyspnoea exertional	19.05	10.95	107	50445	86966	79606870
Eosinophilia	18.97	10.95	3	50549	45342	79648494
Neuropathy peripheral	18.52	10.95	153	50399	141152	79552684
Folliculitis	18.52	10.95	6	50546	55374	79638462
Blood potassium decreased	18.32	10.95	68	50484	46444	79647392
Small intestinal obstruction	18.31	10.95	48	50504	27224	79666612
Multiple organ dysfunction syndrome	18.27	10.95	30	50522	120216	79573620
Eye swelling	18.20	10.95	47	50505	26421	79667415
Interstitial lung disease	18.15	10.95	27	50525	112573	79581263
Pulmonary arterial hypertension	18.11	10.95	49	50503	28317	79665519
Nasal congestion	18.04	10.95	96	50456	76456	79617380
Injection site erythema	17.71	10.95	97	50455	78100	79615736
Platelet count decreased	17.68	10.95	195	50357	194469	79499367
Injection site haemorrhage	17.65	10.95	48	50504	27822	79666014
Wound	17.64	10.95	29	50523	116150	79577686
COVID-19	17.52	10.95	47	50505	157627	79536209
Multiple sclerosis relapse	17.48	10.95	67	50485	46466	79647370
White blood cell count decreased	17.27	10.95	189	50363	188099	79505737
Constipation	17.06	10.95	263	50289	282787	79411049
Cholestasis	16.81	10.95	6	50546	52103	79641733
Hypoaesthesia	16.44	10.95	180	50372	179172	79514664
Complication associated with device	16.32	10.95	35	50517	17461	79676375
Pulmonary hypertension	16.27	10.95	67	50485	48013	79645823
Haematocrit decreased	15.92	10.95	79	50473	61233	79632603
Back pain	15.87	10.95	276	50276	303904	79389932
Hypoxia	15.86	10.95	116	50436	103127	79590709
Dysgeusia	15.80	10.95	75	50477	57102	79636734
Irritable bowel syndrome	15.74	10.95	10	50542	62231	79631605
Illness	15.62	10.95	5	50547	46506	79647330
Cardiac failure congestive	15.47	10.95	148	50404	142254	79551582
Cytomegalovirus infection	15.40	10.95	4	50548	42640	79651196
Eructation	15.35	10.95	26	50526	10883	79682953
Drug reaction with eosinophilia and systemic symptoms	15.34	10.95	11	50541	64233	79629603
Product complaint	15.19	10.95	29	50523	13320	79680516
Hospitalisation	15.13	10.95	107	50445	94129	79599707
Agranulocytosis	14.84	10.95	5	50547	45025	79648811
Oedema peripheral	14.66	10.95	233	50319	252055	79441781
Weight decreased	14.35	10.95	310	50242	354888	79338948
Pleural effusion	14.34	10.95	148	50404	145114	79548722
Urinary tract infection	14.29	10.95	249	50303	274263	79419573
Cellulitis	14.24	10.95	118	50434	108942	79584894
Vaginal haemorrhage	14.24	10.95	38	50514	21779	79672057
Memory impairment	14.12	10.95	120	50432	111614	79582222
Abdominal pain	13.88	10.95	334	50218	389235	79304601
Transfusion	13.77	10.95	37	50515	21293	79672543
Cytokine release syndrome	13.74	10.95	3	50549	35995	79657841
Laboratory test abnormal	13.66	10.95	44	50508	28004	79665832
Rhabdomyolysis	13.65	10.95	28	50524	103103	79590733
Condition aggravated	13.47	10.95	230	50322	500894	79192942
Flushing	13.46	10.95	99	50453	88169	79605667
Renal impairment	13.38	10.95	53	50499	157730	79536106
Drug resistance	13.38	10.95	5	50547	42208	79651628
Abdominal distension	13.32	10.95	125	50427	119525	79574311
Tremor	13.06	10.95	165	50387	169918	79523918
Disease progression	12.96	10.95	176	50376	184186	79509650
Chest pain	12.92	10.95	251	50301	282053	79411783
Diabetes mellitus	12.44	10.95	19	50533	78371	79615465
Cardio-respiratory arrest	12.31	10.95	32	50520	108478	79585358
Exposure during pregnancy	12.12	10.95	29	50523	101103	79592733
Chills	12.11	10.95	155	50397	160079	79533757
Thrombosis	12.08	10.95	93	50459	84007	79609829
Anxiety	12.07	10.95	223	50329	248289	79445547
Laryngeal pain	12.01	10.95	17	50535	6097	79687739
Cardiac disorder	11.95	10.95	77	50475	65680	79628156
Heavy menstrual bleeding	11.90	10.95	27	50525	13984	79679852
Fibromyalgia	11.82	10.95	14	50538	64326	79629510
Rotator cuff syndrome	11.80	10.95	27	50525	14068	79679768
Asthma	11.70	10.95	45	50507	135050	79558786
Application site discolouration	11.38	10.95	7	50545	857	79692979
Rash pruritic	11.30	10.95	81	50471	71548	79622288
International normalised ratio increased	11.24	10.95	92	50460	84629	79609207
Application site erythema	11.23	10.95	15	50537	5095	79688741
Bone pain	11.21	10.95	67	50485	55675	79638161
Drug eruption	11.19	10.95	7	50545	43928	79649908
Infective pulmonary exacerbation of cystic fibrosis	11.18	10.95	25	50527	12826	79681010
Intestinal dilatation	11.18	10.95	11	50541	2689	79691147
Prescribed overdose	11.17	10.95	5	50547	37878	79655958
Altered state of consciousness	11.14	10.95	7	50545	43815	79650021
Gait disturbance	11.07	10.95	189	50363	207317	79486519
Bronchitis	11.01	10.95	129	50423	130515	79563321
Atelectasis	10.95	10.95	45	50507	32212	79661624

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AB20	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes
CHEBI has role	CHEBI:33287	fertilizers
CHEBI has role	CHEBI:139492	sensitizers
CHEBI has role	CHEBI:149552	emetics
MeSH PA	D000931	Antidotes
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004639	Emetics
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypocupremia	contraindication	19577007
Wilson's disease	contraindication	88518009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML)	TRALEMENT	AM REGENT	N209376	July 2, 2020	RX	SOLUTION	INTRAVENOUS	April 30, 2024	NEW CHEMICAL ENTITY
EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML)	TRALEMENT	AM REGENT	N209376	Dec. 2, 2020	RX	SOLUTION	INTRAVENOUS	April 30, 2024	NEW CHEMICAL ENTITY
EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML)	MULTRYS	AM REGENT	N209376	June 30, 2021	RX	SOLUTION	INTRAVENOUS	April 30, 2024	NEW CHEMICAL ENTITY

Bioactivity Summary:

None

External reference:

ID	Source
4020097	VUID
N0000148098	NUI
D03613	KEGG_DRUG
7758-98-7	SECONDARY_CAS_RN
4017628	VANDF
4017650	VANDF
4017708	VANDF
4020097	VANDF
C0056301	UMLSCUI
CHEBI:23414	CHEBI
CHEMBL604	ChEMBL_ID
D019327	MESH_DESCRIPTOR_UI
DB06778	DRUGBANK_ID
24462	PUBCHEM_CID
1999541	RXNORM
3686	MMSL
37539	MMSL
39943	MMSL
4503	MMSL
4513	MMSL
6110	MMSL
72601	MMSL
d04204	MMSL
000855	NDDF
001946	NDDF
007446	NDDF
423960007	SNOMEDCT_US
70168001	SNOMEDCT_US
LRX7AJ16DT	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Multitrace-4 Neonatal	HUMAN PRESCRIPTION DRUG LABEL	4	0517-6202	INJECTION, SOLUTION	0.39 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace-5	HUMAN PRESCRIPTION DRUG LABEL	5	0517-8201	INJECTION, SOLUTION, CONCENTRATE	3.93 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace-5	HUMAN PRESCRIPTION DRUG LABEL	5	0517-8210	INJECTION, SOLUTION, CONCENTRATE	3.93 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace-5	HUMAN PRESCRIPTION DRUG LABEL	5	0517-8510	INJECTION, SOLUTION	1.57 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multitrace -4 Pediatric	HUMAN PRESCRIPTION DRUG LABEL	4	0517-9203	INJECTION, SOLUTION, CONCENTRATE	0.40 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Multrys	HUMAN PRESCRIPTION DRUG LABEL	4	0517-9302	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	19 sections
Tralement	HUMAN PRESCRIPTION DRUG LABEL	4	0517-9305	INJECTION, SOLUTION	0.30 mg	INTRAVENOUS	NDA	22 sections
Trace Elements 4	HUMAN PRESCRIPTION DRUG LABEL	4	0517-9310	INJECTION, SOLUTION	0.40 mg	INTRAVENOUS	UNAPPROVED DRUG OTHER	14 sections
Strovite One Caplets	HUMAN PRESCRIPTION DRUG LABEL	20	0642-0207	TABLET	1.50 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
Strovite One Caplets	HUMAN PRESCRIPTION DRUG LABEL	20	0642-0207	TABLET	1.50 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
Se-Tan PLUS	HUMAN PRESCRIPTION DRUG LABEL	13	13925-118	CAPSULE, GELATIN COATED	0.80 mg	ORAL	unapproved drug other	19 sections
Se-Tan PLUS	HUMAN PRESCRIPTION DRUG LABEL	13	13925-118	CAPSULE, GELATIN COATED	0.80 mg	ORAL	unapproved drug other	19 sections
Quflora Pediatric Drops	HUMAN PRESCRIPTION DRUG LABEL	13	15370-100	LIQUID	1 mg	ORAL	UNAPPROVED DRUG OTHER	11 sections
Quflora Pediatric Drops	HUMAN PRESCRIPTION DRUG LABEL	13	15370-101	LIQUID	1 mg	ORAL	UNAPPROVED DRUG OTHER	11 sections
Quflora Pediatric	HUMAN PRESCRIPTION DRUG LABEL	14	15370-103	TABLET, CHEWABLE	1 mg	ORAL	UNAPPROVED DRUG OTHER	12 sections
Quflora Pediatric	HUMAN PRESCRIPTION DRUG LABEL	14	15370-104	TABLET, CHEWABLE	1 mg	ORAL	UNAPPROVED DRUG OTHER	12 sections
Quflora Pediatric	HUMAN PRESCRIPTION DRUG LABEL	14	15370-105	TABLET, CHEWABLE	1 mg	ORAL	UNAPPROVED DRUG OTHER	12 sections
Centratex	HUMAN PRESCRIPTION DRUG LABEL	13	23359-100	CAPSULE	0.80 mg	ORAL	unapproved drug other	13 sections
C-Nate DHA	HUMAN PRESCRIPTION DRUG LABEL	13	23359-105	CAPSULE, GELATIN COATED	1 mg	ORAL	unapproved drug other	15 sections
Dynamiclear Rapid	HUMAN OTC DRUG LABEL	3	49836-033	LIQUID	40 mg	TOPICAL	EXPORT ONLY	15 sections
Dynamiclear Rapid	HUMAN OTC DRUG LABEL	3	49836-034	LIQUID	40 mg	TOPICAL	EXPORT ONLY	15 sections
Concept OB	HUMAN PRESCRIPTION DRUG LABEL	15	52747-620	CAPSULE	800 ug	ORAL	unapproved drug other	13 sections
Concept OB	HUMAN PRESCRIPTION DRUG LABEL	15	52747-620	CAPSULE	800 ug	ORAL	unapproved drug other	13 sections
Concept DHA	HUMAN PRESCRIPTION DRUG LABEL	15	52747-621	CAPSULE, LIQUID FILLED	2 mg	ORAL	unapproved drug other	7 sections
Concept DHA	HUMAN PRESCRIPTION DRUG LABEL	15	52747-621	CAPSULE, LIQUID FILLED	2 mg	ORAL	unapproved drug other	7 sections
PureVit DualFe Plus	HUMAN PRESCRIPTION DRUG LABEL	13	59088-112	CAPSULE	0.80 mg	ORAL	unapproved drug other	12 sections
PureVit DualFe Plus	HUMAN PRESCRIPTION DRUG LABEL	13	59088-112	CAPSULE	0.80 mg	ORAL	unapproved drug other	12 sections
Dexatran	HUMAN PRESCRIPTION DRUG LABEL	13	59088-643	CAPSULE	0.80 mg	ORAL	unapproved drug other	12 sections
Viva CT Prenatal	HUMAN PRESCRIPTION DRUG LABEL	12	64661-811	TABLET, CHEWABLE	1 mg	ORAL	UNAPPROVED DRUG OTHER	16 sections
TRICARE PRENATAL	HUMAN PRESCRIPTION DRUG LABEL	13	67112-101	TABLET, COATED	2 mg	ORAL	unapproved drug other	12 sections